• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by DuPont de Nemours Inc.

    5/22/24 4:58:56 PM ET
    $DD
    Major Chemicals
    Industrials
    Get the next $DD alert in real time by email
    DEFA14A 1 d804975ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE

    (RULE 14a-101)

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    DuPont de Nemours, Inc.

     

    (Name of Registrant as Specified in Its Charter)

     

        

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


    SUPPLEMENT TO THE PROXY STATEMENT DATED APRIL 5, 2024

    FOR THE ANNUAL MEETING OF STOCKHOLDERS OF

    DUPONT DE NEMOURS, INC.

    TO BE HELD ON MAY 23, 2024

    TO OUR STOCKHOLDERS:

    On or about April 5, 2024, DuPont de Nemours, Inc. (the “Company”) made available a proxy statement (the “Proxy Statement”) to its stockholders describing the matters to be voted on at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Meeting”). The purpose of this supplement is to advise you of (i) a leadership transition announced on May 22, 2024, (ii) certain updated information relating to certain director nominees, and (iii) certain updates to the “Involuntary Termination or Change in Control Values” table in the Proxy Statement, which we are updating to correct certain administrative errors.

    CEO and CFO Succession

    On May 22, 2024, the Company announced that, effective as of June 1, 2024, Edward D. Breen will transition from the role of Chief Executive Officer to full-time Executive Chairman of the Company’s board of directors (the “Board”), Lori D. Koch, the Company’s Chief Financial Officer, will succeed Mr. Breen as Chief Executive Officer, and Antonella B. Franzen is appointed Senior Vice President and Chief Financial Officer. Additionally, Ms. Koch is expected to join the Board at its next regularly scheduled meeting in June 2024. Such leadership transition is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

    Ms. Koch, 49, has served as the Company’s Chief Financial Officer since February 2020. Prior to that, Ms. Koch served as the Company’s Vice President, Investor Relations and Corporate Financial Planning & Analysis since June 2019. Ms. Koch previously served as the Director of Investor Relations of E. I. du Pont de Nemours and Company (“EID”) from July 2016 to May 2019; Global Finance Director of EID’s Performance Materials business from November 2015 to July 2016; and the Global Finance Manager for various EID businesses from April 2008 to November 2015. Additionally, Ms. Koch currently serves as a director of Actylis, a New Mountain Capital LLC portfolio company, and is on the Board of Visitors of the Smeal College of Business at Penn State University.

    Ms. Koch does not have a family relationship with any director or executive officer of the Company. There is no arrangement or understanding between Ms. Koch and any other persons pursuant to which Ms. Koch was selected as Chief Executive Officer of the Company. Ms. Koch does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

    Ms. Franzen, 48, has served as the Chief Financial Officer of the Company’s Water & Protection segment since February 2022. Before joining the Company, Ms. Franzen was Vice President, Chief Investor Relations and Communications Officer at Johnson Controls International. Before the merger of Tyco International with Johnson Controls, Ms. Franzen held various roles of increasing responsibility at Tyco, including leading investor relations, corporate finance and external reporting. Ms. Franzen began her career with PwC, providing assurance advisory services to large multinational public companies in the industrial and pharmaceutical sectors. Ms. Franzen has served on the board of JELD-WEN Holding, Inc. since March 2024.

    Ms. Franzen does not have a family relationship with any director or executive officer of the Company. There is no arrangement or understanding between Ms. Franzen and any other persons pursuant to which Ms. Franzen was selected as Senior Vice President and Chief Financial Officer of the Company. Ms. Franzen does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

    A copy of the press release announcing the above-described transition has been filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Company on May 22, 2024.

    In connection with her promotion to Chief Executive Officer, the Board approved an increase in Ms. Koch’s annual base salary to $1,200,000 and an increase in her target short-term incentive program award to 150% of her base salary. In addition, the Board approved the grant of equity awards with a target grant date value of $6,000,000 to Ms. Koch under the DuPont de Nemours, Inc. 2020 Equity and Incentive Plan (the “EIP”), of which 40% will be granted in the form of time-based restricted stock units and 60% will be granted in the form of performance-based restricted stock units. The time-based restricted stock units will vest annually over three years and the performance-based restricted stock units will vest at the end of a three-year performance period, subject to satisfaction of the performance criteria, and, in each case, generally subject to continued employment. Further, in connection with the above-described transition, Ms. Koch becomes entitled to participate in the DuPont Senior Executive Severance Plan (the “SESP”) at the level of benefits assigned to the “CEO” pursuant to the terms of the SESP, which is incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed June 3, 2019.


    In connection with her promotion to Senior Vice President and Chief Financial Officer, the People and Compensation Committee (the “Committee”) of the Board approved an increase in Ms. Franzen’s annual base salary to $700,000 and an increase in her target short-term incentive program award to 100% of her base salary. In addition, the Board approved the grant of equity awards with a target grant date value of $2,000,000 to Ms. Franzen under the EIP, of which 40% will be granted in the form of time-based restricted stock units and 60% will be granted in the form of performance-based restricted stock units. The time-based restricted stock units will vest annually over three years and the performance-based restricted stock units will vest at the end of the three-year performance period, subject to satisfaction of the performance criteria, and, in each case, generally subject to continued employment. Further, the Committee designated Ms. Franzen as a participant in the SESP.

    In connection with the above-described transition, the terms described in Mr. Breen’s letter agreement, dated February 6, 2023, remain unchanged and it is incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 7, 2023.

    Updated Biographies of Certain Director Nominees

    Effective as of May 6, 2024, Deanna M. Mulligan resigned as a director of The Vanguard Group, Inc. and Trustee of the Vanguard Funds, and effective as of April 23, 2024, Frederick M. Lowery was promoted to Executive Vice President and President, Laboratory Products and BioProduction, of Thermo Fisher Scientific Inc. Accordingly, this supplement updates the biographies of such director nominees on page 28 of the Proxy Statement as follows (deleted text in strikethrough and new text in bold and italics):

     

     

    LOGO

     

    Age: 53

     

    Director Since: 2019

     

    Committees:

    People and Compensation (Chair); Environment, Health, Safety & Sustainability

     

    Other Public Boards:

    None

      

    Frederick M. Lowery

     

    Senior Vice President and President, Customer Channels, Executive Vice President and President, Laboratory Products and BioProduction, Thermo Fisher Scientific Inc.

    Mr. Lowery has served as Senior Vice President and President, Customer Channels, Executive Vice President and President, Laboratory Products and BioProduction, of Thermo Fisher Scientific Inc. since April 2024 January 2021. In January 2022, Mr. Lowery also assumed responsibility for Thermo Fisher’s business in Europe, the Middle East and Africa. Since joining Thermo Fisher in 2005, he has held several senior leadership positions across Thermo Fisher, including previously serving as President, Life Sciences Solutions and Laboratory Products, and Senior Vice President and President, Customer Channels. Prior to his time at Thermo Fisher, Mr. Lowery was with Maytag Corporation from 1999 to 2005 and began his career as an engineer at General Motors Company. Mr. Lowery is a member of the Board of Trustees for Boston Medical Center. He is also on the Board of Trustees for both Tennessee Tech and its Foundation. Mr. Lowery joined the DuPont Board of Directors in June 2019.

     

    Skills and Expertise:

     

    With his engineering and science backgrounds, Mr. Lowery brings science and technology perspective combined with senior management capabilities to the Board. Mr. Lowery has a wealth of global experience and has developed operating teams, launched innovative new products and acquired businesses. Additionally, he brings significant manufacturing and global supply chain knowledge and experience.


     

     

    LOGO

     

    Age: 60

     

    Director Since: 2021

     

    Committees:

    Nomination and Governance;

    People and Compensation

     

    Other Public Boards:

    None

      

    Deanna M. Mulligan

     

    Chief Executive Officer, Purposeful

    Ms. Mulligan has served as Chief Executive Officer of Purposeful, an advisory firm, since January 2021. Previously, Ms. Mulligan served as CEO of The Guardian Life Insurance Company of America, a mutual life insurance company (Guardian), from 2019 to October 2020, as President and Chief Executive Officer of Guardian from 2011 to 2019 and as President and Chief Operating Officer of Guardian beginning in 2010. She also served as a member of Guardian’s Board of Directors from 2011 until her retirement at year-end 2020 and as its Board Chair from October 2020 until her retirement date. Ms. Mulligan joined Guardian in 2008 as the Executive Vice President, Individual Life and Disability. Prior to joining Guardian in 2008, Ms. Mulligan founded DMM Management Solutions LLC where she served as President from 2007 to 2008. Previously, she held several other management positions at McKinsey & Company, AXA Financial, Inc. and New York Life Insurance Company. Ms. Mulligan currently serves as a director of The Vanguard Group, Inc., Trustee of the Vanguard Funds, Trustee of New York Presbyterian Hospital, Director of Chief Executives for Corporate Purpose, and Director of Partnership for New York City. She previously served as a director of ARCH Capital Group from 2013 to 2016. Ms. Mulligan joined the DuPont Board of Directors in April 2021.

     

    Skills and Expertise:

     

    Ms. Mulligan possesses deep executive management and leadership, finance, investment, risk management and corporate governance experience as former Board Chair, Director, Chief Executive Officer and President of Guardian and based on her numerous present and former board positions.

    Further, in connection with the above updates to the biography of Frederick M. Lowery, this supplement updates the table of director nominees appearing on pages 3 and 22 of the Proxy Statement as follows (rows for unaffected director nominees omitted) (deleted text in strikethrough and new text in bold and italics):

     

    (As of the date of this Proxy Statement)

    Name

    Age

    Current Position

       Independent    Audit
    Committee
       Nomination
    and
    Governance
    Committee
       People and
    Compensation
    Committee
       Environment,
    Health, Safety
    & Sustainability
    Committee
       Other
    Current
    Public
    Boards

    Frederick M. Lowery

    Senior Vice President and President, Customer Channels, Executive Vice President and President, Laboratory Products and BioProduction, Thermo Fisher Scientific Inc.

      

     

    ●

      

     

         

     

    CH

      

     

    ●

      

    Updated Involuntary Termination or Change in Control Values

    This supplement updates the Involuntary Termination or Change in Control Values disclosure appearing on pages 68-69 of the Proxy Statement (table reflects deleted text in strikethrough and new text in bold and italics), which is updated to correct certain administrative errors.


    Involuntary Termination or Change in Control Values

     

    Name

      

    Type of Benefit

       Involuntary
    Termination Without
    Cause
    ($)(a)
        Change in Control
    ($)(b)
     

    Edward D. Breen

       Severance      —  (c)      —  (c) 
       LTI Acceleration(d)     

    8,686,541

    15,835,261

     

     

       

    8,686,541

     25,838,161

     

     

       Increase in Present Value of Pension      N/A       N/A  
       Health & Welfare Benefits      48,258       48,258  
       Outplacement & Financial Planning      29,900       29,900  
         Tax Reimbursement      N/A       N/A  

    Lori D. Koch

       Severance      3,000,000       3,750,000  
       LTI Acceleration     

    2,203,668

    3,919,438

     

     

       

    2,203,668

     6,320,116

     

     

       Increase in Present Value of Pension      —        —   
       Health & Welfare Benefits      32,620       43,494  
       Outplacement & Financial Planning      23,071       23,071  
         Tax Reimbursement      N/A       N/A  

    Erik T. Hoover

       Severance      2,500,000       3,125,000  
       LTI Acceleration     

    1,074,935

    1,932,781

     

     

       

    1,074,935

     3,133,274

     

     

       Increase in Present Value of Pension      N/A       N/A  
       Health & Welfare Benefits      32,620       43,494  
       Outplacement & Financial Planning      23,071       23,071  
       Tax Reimbursement      N/A       N/A  


    Jon Kemp

       Severance          2,600,000            3,250,000  
       LTI Acceleration     

    3,567,145

     4,567,927

     

     

        

    3,567,145

     5,968,438

     

     

       Increase in Present Value of Pension      —         —   
       Health & Welfare Benefits      32,620        43,494  
       Outplacement & Financial Planning      23,071        23,071  
         Tax Reimbursement      N/A        N/A  

    Leland Weaver

       Severance      2,200,000        2,750,000  
       LTI Acceleration     

    1,270,019

     2,127,865

     

     

        

    1,270,019

     3,328,358

     

     

       Increase in Present Value of Pension      —         —   
       Health & Welfare Benefits      16,303        21,737  
       Outplacement & Financial Planning      23,071        23,071  
         Tax Reimbursement      N/A        N/A  

    Raj Ratnakar(e)

       Severance      2,248,767        N/A  
       LTI Acceleration     

    814,850

    1,366,667

     

     

         N/A  
       Increase in Present Value of Pension      N/A        N/A  
       Health & Welfare Benefits      32,620        N/A  
       Outplacement & Financial Planning      23,071        N/A  
       Tax Reimbursement      N/A        N/A  

     

    (a)

    LTI Acceleration assumes PSUs achieved the target level of performance.

    (b)

    An executive must meet the double trigger requirement of being involuntarily terminated within two years of a change in control in order to receive benefits. LTI Acceleration assumes outstanding LTI awards are not assumed or substituted or, if assumed or substituted, executive’s employment is terminated without cause or executive resigns with good reason, in either case, within two years of a change in control. LTI awards are deemed fully vested and any performance conditions imposed with respect to PSUs are deemed to be achieved at the target level of performance.

    (c)

    As noted above, Mr. Breen is not entitled to cash severance payments under the SESP (and was not entitled to cash severance payments under the legacy version of the SESP). The $5,000,000 retention payment that was paid to Mr. Breen effective as of December 31, 2023 under his 2020 Agreement is also not reflected in this table because he became entitled to such payment by virtue of his continued employment through that date and accordingly it is reflected in the Summary Compensation Table as an amount earned for 2023. For a description of Mr. Breen’s employment agreements, see “E. Breen Employment Agreement” above.

    (d)

    Excludes LTI awards granted to Mr. Breen in his capacity as a non-employee director prior to his being named CEO of EID.

    (e)

    Amounts listed for Mr. Ratnakar are actual values paid upon involuntary termination without cause effective September 30, 2023. The severance includes a pro-rated STIP at target.

    This supplement to the Proxy Statement is first being released to stockholders on or about May 22, 2024, and should be read together with the Proxy Statement. Other than the updates noted above, no changes are otherwise being made to the Proxy Statement or the proxy card for the 2024 Meeting, as filed with the Securities and Exchange Commission and previously delivered or otherwise made available to stockholders of record as of March 28, 2024. The information contained in this supplement to the Proxy Statement modifies or supersedes any inconsistent information contained in the Proxy Statement.

    * * *

    As described in the Proxy Statement, the 2024 Meeting will be a virtual meeting and will be held on Thursday, May 23, 2024 at 1:00 p.m., Eastern Time, online at www.virtualshareholdermeeting.com/DD2024.


    Your vote is important. Information regarding how to vote your shares is available in the Proxy Statement. If you have not already voted, you are urged to vote by proxy as soon as possible over the Internet as instructed in the Notice of the Annual Meeting of Stockholders or, if you receive paper copies of the proxy materials by mail, you can also vote by following the instructions on your proxy card or other voting instruction form. If you have already voted, you do not need to take any action unless you wish to change your vote.

    If you have already voted and would like to revoke your proxy or voting instructions at any time before their use at the 2024 Meeting, you may do so by sending a written revocation, by submitting another proxy or voting form on a later date, or by voting virtually at the 2024 Meeting. No matter which voting method you choose, however, you should not vote any single account more than once unless you wish to change your vote. Be sure to submit votes for each separate account in which you hold common stock of the Company.

    Only stockholders of record at the close of business on March 28, 2024 or their proxy holders may vote at the 2024 Meeting.

    The Proxy Statement, along with the supplemental proxy materials and the Company’s Annual Report for the year ended December 31, 2023, are available at www.proxyvote.com.

    Thank you for your continued support and your interest in DuPont de Nemours, Inc.

     

    LOGO

    Peter W. Hennessey

    Vice President, Associate General Counsel and Corporate Secretary

    May 22, 2024

    Get the next $DD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DD

    DatePrice TargetRatingAnalyst
    7/3/2025$75.00 → $85.00Buy
    Citigroup
    4/15/2025$75.00Underperform → Neutral
    BofA Securities
    4/14/2025$81.00Sector Weight → Overweight
    KeyBanc Capital Markets
    2/13/2025$85.00 → $89.00Underweight → Equal Weight
    Barclays
    1/17/2025$91.00Peer Perform → Outperform
    Wolfe Research
    10/7/2024$88.00 → $84.00Equal Weight → Underweight
    Barclays
    5/28/2024$85.00 → $95.00Neutral → Buy
    Citigroup
    5/24/2024$80.00 → $103.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $DD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Macpherson Donald G claimed no ownership of stock in the company (SEC Form 3)

    3 - DuPont de Nemours, Inc. (0001666700) (Issuer)

    1/28/26 4:38:13 PM ET
    $DD
    Major Chemicals
    Industrials

    Director Breen Edward D covered exercise/tax liability with 24,574 shares, decreasing direct ownership by 8% to 301,048 units (SEC Form 4)

    4 - DuPont de Nemours, Inc. (0001666700) (Issuer)

    1/5/26 5:00:20 PM ET
    $DD
    Major Chemicals
    Industrials

    Senior Vice President & CHRO Raia Christopher covered exercise/tax liability with 2,793 shares, decreasing direct ownership by 3% to 80,255 units (SEC Form 4)

    4 - DuPont de Nemours, Inc. (0001666700) (Issuer)

    1/5/26 4:59:10 PM ET
    $DD
    Major Chemicals
    Industrials

    $DD
    SEC Filings

    View All

    DuPont de Nemours Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DuPont de Nemours, Inc. (0001666700) (Filer)

    2/10/26 6:06:47 AM ET
    $DD
    Major Chemicals
    Industrials

    DuPont de Nemours Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DuPont de Nemours, Inc. (0001666700) (Filer)

    1/20/26 5:00:08 PM ET
    $DD
    Major Chemicals
    Industrials

    DuPont de Nemours Inc. filed SEC Form 8-K: Other Events

    8-K - DuPont de Nemours, Inc. (0001666700) (Filer)

    12/4/25 4:42:35 PM ET
    $DD
    Major Chemicals
    Industrials

    $DD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DuPont Named Finalist in 2026 Edison Awards for FilmTec™ Fortilife™ XC160UHP Membrane for Wastewater Treatment and Reuse

    WILMINGTON, Del., Feb. 12, 2026 /PRNewswire/ -- DuPont (NYSE:DD) is proud to announce that its FilmTec™ Fortilife™ XC160UHP reverse osmosis elements for industrial wastewater treatment and reuse, has been honored as a finalist in the 2026 Edison Awards in the Water, Food and Agriculture category.  The FilmTec™ Fortilife™ XC160UHP element is a reverse osmosis element designed to concentrate wastewater streams, providing a more efficient and sustainable approach to water reuse and wastewater treatment. With the ability to operate under ultra-high-pressure conditions, FilmTec™ Fo

    2/12/26 9:00:00 AM ET
    $DD
    Major Chemicals
    Industrials

    DuPont Reports Fourth Quarter and Full Year 2025 Results

    Exceeds Fourth Quarter and Full Year 2025 Guidance Initiates First Quarter and Full Year 2026 Guidance  Fourth Quarter 2025 Highlights Net Sales of $1.7 billion were flat; organic sales decreased 1% versus year-ago period including a $30 million, or 2%, headwind from the third quarter timing shiftGAAP Loss from continuing operations of $(108) million; operating EBITDA of $409 millionGAAP EPS from continuing operations of $(0.27); adjusted EPS of $0.46Cash provided by operating activities from continuing operations of $87 million, including $228 million of separation-related transaction cost and other payments; transaction-adjusted free cash flow of $228 millionFull Year 2025 Highlights Net S

    2/10/26 6:00:00 AM ET
    $DD
    Major Chemicals
    Industrials

    DuPont Expands Dairy Reverse Osmosis Portfolio with Mesh Wrapped FilmTec™ MXP RO-8038-FF Element

    New FilmTec™ MXP RO-8038-FF reverse osmosis element provides enhanced productivity and operational performance in a mesh wrapped configuration, enabling high-quality dairy products WILMINGTON, Del., Feb. 4, 2026 /PRNewswire/ -- DuPont (NYSE:DD) today announced the launch of the FilmTec™ MXP RO-8038-FF element—an advanced mesh wrapped reverse osmosis solution engineered for dairy processors who rely on mesh wrapped systems and now seek greater active area and higher productivity. As dairy producers seek to maximize throughput while maintaining trusted operational practices, Fil

    2/4/26 9:00:00 AM ET
    $DD
    Major Chemicals
    Industrials

    $DD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup reiterated coverage on DuPont with a new price target

    Citigroup reiterated coverage of DuPont with a rating of Buy and set a new price target of $85.00 from $75.00 previously

    7/3/25 9:18:04 AM ET
    $DD
    Major Chemicals
    Industrials

    DuPont upgraded by BofA Securities with a new price target

    BofA Securities upgraded DuPont from Underperform to Neutral and set a new price target of $75.00

    4/15/25 8:43:17 AM ET
    $DD
    Major Chemicals
    Industrials

    DuPont upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded DuPont from Sector Weight to Overweight and set a new price target of $81.00

    4/14/25 8:04:47 AM ET
    $DD
    Major Chemicals
    Industrials

    $DD
    Financials

    Live finance-specific insights

    View All

    DuPont Reports Fourth Quarter and Full Year 2025 Results

    Exceeds Fourth Quarter and Full Year 2025 Guidance Initiates First Quarter and Full Year 2026 Guidance  Fourth Quarter 2025 Highlights Net Sales of $1.7 billion were flat; organic sales decreased 1% versus year-ago period including a $30 million, or 2%, headwind from the third quarter timing shiftGAAP Loss from continuing operations of $(108) million; operating EBITDA of $409 millionGAAP EPS from continuing operations of $(0.27); adjusted EPS of $0.46Cash provided by operating activities from continuing operations of $87 million, including $228 million of separation-related transaction cost and other payments; transaction-adjusted free cash flow of $228 millionFull Year 2025 Highlights Net S

    2/10/26 6:00:00 AM ET
    $DD
    Major Chemicals
    Industrials

    DuPont Schedules Fourth Quarter 2025 Earnings Conference Call

    WILMINGTON, Del., Jan. 21, 2026 /PRNewswire/ -- DuPont (NYSE:DD) will release its fourth quarter and full year 2025 financial results at 6:00 a.m. ET on Tuesday, February 10, 2026. In addition, the company will host a conference call at 8:00 a.m. ET that day. The event will be webcast live and can be accessed on DuPont's Investors Relations webpage. A replay, along with the earnings release and supporting materials, will also be posted to the website. The dial-in number for the conference call is 888-440-4172 toll-free within the U.S. or +1-646-960-0673. The conference ID is 5

    1/21/26 8:00:00 AM ET
    $DD
    Major Chemicals
    Industrials

    DuPont Reports Third Quarter 2025 Results; Announces Plans to Return Cash to Shareholders

    Exceeds 3Q 2025 Guidance for Total DuPont Raises FY 2025 Earnings Guidance for New DuPont Announces $2 Billion Share Repurchase Authorization, $500 Million Accelerated Share Repurchase and New DuPont Quarterly Dividend Third Quarter 2025 Highlights Net Sales of $3.1 billion increased 7%; organic sales increased 6% versus year-ago periodGAAP Income from continuing operations of $308 million; operating EBITDA of $840 millionGAAP EPS from continuing operations of $0.70; adjusted EPS of $1.09Cash provided by operating activities from continuing operations of $591 million; transaction-adjusted free cash flow of $576 millionRaises FY 2025 operating EBITDA guidance for new DuPont to $1.6 billionCap

    11/6/25 6:00:00 AM ET
    $DD
    Major Chemicals
    Industrials

    $DD
    Leadership Updates

    Live Leadership Updates

    View All

    DuPont Announces Appointment of D.G. Macpherson to Board of Directors

    WILMINGTON, Del., Jan. 20, 2026 /PRNewswire/ -- DuPont (NYSE:DD) today announced the appointment of D.G. Macpherson to its Board of Directors, effective immediately. "We are very pleased to welcome D.G. to the DuPont board," said Lori Koch, DuPont Chief Executive Officer. "D.G. brings deep expertise in operational excellence, supply chain optimization, and business transformation, which will be invaluable as we execute our growth strategy and deliver long-term value to shareholders, customers, and employees. His passion for innovation and commitment to continuous improvement m

    1/20/26 4:15:00 PM ET
    $DD
    Major Chemicals
    Industrials

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    DuPont Announces Appointment of Kurt McMaken to Board of Directors

    WILMINGTON, Del., Feb. 21, 2025 /PRNewswire/ -- DuPont (NYSE:DD) today announced the appointment of Kurt McMaken to its Board of Directors, effective immediately. Mr. McMaken will serve on the Audit committee and Nomination and Governance committee. "We are pleased to welcome Kurt to DuPont's Board of Directors," said DuPont Executive Chairman Ed Breen. "Kurt's global business expertise in the manufacturing sector and extensive background in finance and strategic planning make him well suited to help guide DuPont's growth and value creation strategies. We look forward to his c

    2/21/25 4:15:00 PM ET
    $DD
    Major Chemicals
    Industrials

    $DD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DuPont de Nemours Inc.

    SC 13G/A - DuPont de Nemours, Inc. (0001666700) (Subject)

    11/12/24 11:54:03 AM ET
    $DD
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by DuPont de Nemours Inc. (Amendment)

    SC 13G/A - DuPont de Nemours, Inc. (0001666700) (Subject)

    2/13/24 4:55:53 PM ET
    $DD
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by DuPont de Nemours Inc.

    SC 13G - DuPont de Nemours, Inc. (0001666700) (Subject)

    2/9/24 11:49:03 AM ET
    $DD
    Major Chemicals
    Industrials